Dupilumab in the Treatment of Severe Uncontrolled Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and Comorbid Asthma—A Multidisciplinary Monocentric Real-Life Study
Authors:
- Gian Luca FaddaGian Luca Fadda
- Chiara RustichelliCRChiara Rustichelli
- Simone SoccalSSSimone Soccal
- Simone MoglioSMSimone Moglio
- Alessandro SerroneAlessandro Serrone
- Francesca BertoliniFBFrancesca Bertolini
- Vitina CarrieroVCVitina Carriero
- Stefano PizzimentiSPStefano Pizzimenti
- Stefano LevraSLStefano Levra
- Giovanni CavalloGiovanni Cavallo
- Fabio Luigi Massimo RicciardoloFRFabio Luigi Massimo Ricciardolo
- Giuseppe GuidaGGGiuseppe Guida
Open Access
- 17 February 2025
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 13 (2) , 501
Abstract
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma are mutually correlated with Type-2 inflammation. Dupilumab is effective in uncontrolled and relapsing CRSwNP. However, the precise characterization of Type-2 inflammation and the impact of previous surgery on clinical outcomes need clarification. Methods: We present a prospective observational study on a 38 CRSwNP-patient cohort, whose Type-2 endotype was confirmed after a multidisciplinary approach shared among ENTs, pneumologists and allergologists. Patients were treated with dupilumab and evaluated at 15 days and 1-3-6-12-18-24-30 months, focusing on clinical (VAS, nasal polyp score—NPS), radiological (Lund-Mackay) and quality of life (SNOT-22) parameters, as well olfactory function, asthma control, variation of Type-2 markers and number and extent (ACCESS score) of previous surgeries. Results: We confirmed the efficacy of dupilumab in total and sub-items VAS, NPS, SNOT-22 and sniffing score, as well as Lund–Mackay score improvements, observable and significant after 2 weeks of treatment (p < 0.0001) and long-lasting over 30 months. Good to excellent response criteria to biologic treatment at 6 months was observed in 30/32 patients. Comorbid asthma reached rapid control (p < 0.0001) and exhaled nitric oxide normalization was achieved. One single “not adequate” surgery showed a trend to milder improvement, as well as a higher ACCESS score to better olfactory outcome. Conclusions: The accurate selection of uncontrolled relapsing CRSwNP in terms of Type-2 endotyping by multidisciplinary approach can maximize dupilumab efficacy. The number and extent of previous surgeries may differentiate the response, although this effect is difficult to catch in real life. “Adequate” ESS surgery before dupilumab may drive mostly effective disease control.Keywords
This publication has 32 references indexed in Scilit:
- Efficacy of dupilumab for severe chronic rhinosinusitis with nasal polyps and asthmaAnnals of Allergy, Asthma & Immunology, 2024
- Efficacy and safety of dupilumab in the treatment of CRSwNP in the real-life setting: a review of the literatureEuropean Archives of Oto-Rhino-Laryngology, 2024
- The value of biomarkers in the therapy of CRSwNP with biologicals—a long-term follow-up of dupilumab therapyEuropean Archives of Oto-Rhino-Laryngology, 2024
- Efficacy of dupilumab in real-life settings: a STROBE studyEuropean Archives of Oto-Rhino-Laryngology, 2024
- Correlation between inflammatory biomarkers and disease control in chronic rhinosinusitis with nasal polypsInternational Forum of Allergy & Rhinology, 2024
- Histopathologic features of biologic therapy nonresponders in chronic rhinosinusitis with nasal polyposisInternational Forum of Allergy & Rhinology, 2023
- Influence of Prior Endoscopic Sinus Surgery Extent on Dupilumab Effectiveness in CRSwNP PatientsThe Laryngoscope, 2023
- A comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposisInternational Forum of Allergy & Rhinology, 2022
- Cost Utility Analysis of Dupilumab Versus Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal PolypsThe Laryngoscope, 2020
- High tissue eosinophilia as a marker to predict recurrence for eosinophilic chronic rhinosinusitis: a systematic review and meta‐analysisInternational Forum of Allergy & Rhinology, 2018